Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6414717 | 0.92 | POLB (0.45) | DRD4POLBMEN1KMT2ANPC1 | |
| SCHEMBL6414031 | 0.91 | POLB (0.44) | DRD4POLBMEN1KMT2ANPC1 | |
| SCHEMBL6190898 | 0.87 | POLB (0.44) | TDP1POLBMEN1KMT2ANPC1 | |
| SCHEMBL6190892 | 0.85 | HSD17B10 (0.53) | DRD4POLBMEN1KMT2AMAPT | |
| SCHEMBL6176786 | 0.85 | POLB (0.51) | DRD4POLBMEN1KMT2ANPC1 | |
| SCHEMBL6419494 | 0.84 | POLB (0.50) | POLBMEN1KMT2ANPC1L3MBTL1 | |
| SCHEMBL6414971 | 0.84 | POLB (0.50) | DRD4POLBMEN1KMT2ANPC1 | |
| SCHEMBL6414969 | 0.83 | POLB (0.49) | POLBMEN1KMT2ANPC1L3MBTL1 | |
| SCHEMBL5657975 | 0.82 | MAPT (0.59) | MEN1KMT2ANPC1L3MBTL1KDM4E | |
| SCHEMBL14457597 | 0.81 | DRD2 (0.52) | TDP1POLBMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267126-A1 | Compounds derived from aryl carbamates, preparation thereof and uses of same | CEREP (FR) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267126-A1 | Compounds derived from aryl carbamates, preparation thereof and uses of same | HTR4, HTR2B, HTR1B | TDP1 3183/4885DRD4 39/4885HRH3 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.